Enhanced involvement of endothelin in the haemodynamic sequelae of endotoxaemia in conscious, hypertensive, transgenic ((mRen-2)27) rats

This publication has 21 references indexed in Scilit:

• Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats
  British Journal of Pharmacology, 1997
• Temporal differences between the involvement of angiotensin II and endothelin in the cardiovascular responses to endotoxaemia in conscious rats
  British Journal of Pharmacology, 1996
• Influence of aminoguanidine and the endothelin antagonist, SB 209670, on the regional haemodynamic effects of endotoxaemia in conscious rats
  British Journal of Pharmacology, 1996
• Effects of dexamethasone and SB 209670 on the regional haemodynamic responses to lipopolysaccharide in conscious rats
  British Journal of Pharmacology, 1996
• Regional haemodynamic effects of antagonists of angiotensin II, endothelin and adrenoceptors in conscious, vasopressin‐deficient, genetically hypertensive rats
  British Journal of Pharmacology, 1996
• Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats
  British Journal of Pharmacology, 1995
• Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats
  British Journal of Pharmacology, 1995
• Enhancement of the hypotensive and vasodilator effects of endotoxaemia in conscious rats by the endothelin antagonist, SB 209670
  British Journal of Pharmacology, 1995
• Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670
  Hypertension, 1995
• In vivo pharmacological characterization of the non-peptide endothelin receptor antagonist SB 209670
  British Journal of Pharmacology, 1995